| 11.09.12 |
Visterra Secures Financing From Gates Foundation and Omega to Close $26M Series A Financing Read more »  |
| 10.29.12 |
Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against the H5N1 (Avian Flu) Influenza Strain in Hanoi, Viet Nam Read more » |
| 10.20.12 |
Visterra Presents Data on Broadly Neutralizing Influenza Antibodies at the Infectious Diseases Society of America (IDSA) Meeting Read more » |
| 09.11.12 |
Visterra Appoints Donna M. Ambrosino as Chief Medical Officer Read more » |
| 09.11.12 |
Visterra Signs Antibody Discovery Collaboration Deal With Pfizer Read more » |
| 09.10.12 |
Visterra Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza with VIS410, a Novel Engineered Human Antibody Read more » |
